Sign Up And Receive Our Latest Promotions!
.svg){kind=small}
Clinics & Hospitals
Healthcare providers rely on data for decisions, but much of the data in clinics and hospitals is decentralized and disparate in nature. Generally, data is on closed systems, inaccessible or unable to aggregate with other data for enterprise-wide insights. This creates operational inefficiencies, gaps to understanding outcomes and identifying the right candidates for clinical studies.
RetinAI Discovery is a CE-Marked medical image and data management platform with certified AI Models to aggregate data and extract automatic insights on patient diseases and outcomes. The platform can be configured to connect to PACS or integrate via API calls with the clinic systems.
Use cases for Clinics & Hospitals
RetinAI Discovery has been deployed with a major Ophthalmology hospital to aggregate over 100,000 datasets across multiple imaging types.
Ophthalmologists in this setting have a single medical and imaging data platform via Discovery that is secure, cloud-based and provides real-time data access.
RetinAI's AI models can be used to analyze patient-level data to identify biomarkers and automatically segment and quantify fluid and layers in retinal pathologies.
The models have supported identification of subgroups of patients related to disease progression and treatment outcomes, accelerating participation in clinical trials.
RetinAI Discovery is a platform for participative research and management. Users of the platform can easily share cases with other users granted access, anytime from anywhere.
Interested in learning more?
*Disclaimer
RetinAI Discovery® platform, RetinAI OCT Atlas® and Macula Biomarkers, as well as LuxIA® (Diabetic Retinopathy Screening model) are CE-marked medical devices in accordance with the Medical Devices Regulation (EU) 2017/745 (CE2797). RetinAI Discovery® platform is also a medical device cleared for clinical use by the FDA. The AI modules for biomarkers, fluid, and layer segmentation and quantification in retinal pathologies are designated as Research Use Only (RUO) in the USA. Please be advised that these tools are not intended to replace professional medical advice, diagnosis, or treatment. We do not warrant or guarantee the clinical accuracy, completeness, or usefulness of any content provided by RUO products. For more information, please read our Privacy Notice (https://www.retinai.com/privacy-policy) and Data Processing Agreement (https://www.retinai.com/data-processing-agreement).
RetinAI Discovery® and RetinAI® are trademarks of Ikerian AG.
